Transient ischaemic attacks: New approaches to management

Ramesh Madhavan, Seemant Chaturvedi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modern transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium. Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic attacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.

Original languageEnglish (US)
Pages (from-to)293-305
Number of pages13
JournalCNS Drugs
Volume17
Issue number5
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Transient Ischemic Attack
Stroke
Clinical Trials
Pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Estrogen Replacement Therapy
Platelet Aggregation Inhibitors
Warfarin
Angiotensin-Converting Enzyme Inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Transient ischaemic attacks : New approaches to management. / Madhavan, Ramesh; Chaturvedi, Seemant.

In: CNS Drugs, Vol. 17, No. 5, 2003, p. 293-305.

Research output: Contribution to journalArticle

Madhavan, Ramesh ; Chaturvedi, Seemant. / Transient ischaemic attacks : New approaches to management. In: CNS Drugs. 2003 ; Vol. 17, No. 5. pp. 293-305.
@article{04c15a75687f431a8d93d21727f70891,
title = "Transient ischaemic attacks: New approaches to management",
abstract = "The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modern transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium. Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic attacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.",
author = "Ramesh Madhavan and Seemant Chaturvedi",
year = "2003",
doi = "10.2165/00023210-200317050-00001",
language = "English (US)",
volume = "17",
pages = "293--305",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Transient ischaemic attacks

T2 - New approaches to management

AU - Madhavan, Ramesh

AU - Chaturvedi, Seemant

PY - 2003

Y1 - 2003

N2 - The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modern transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium. Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic attacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.

AB - The fact that transient ischaemic attacks are a harbinger for the possible development of ischaemic stroke has been recognised for several decades. However, within the past decade, our concepts regarding transient ischaemic attacks as a distinct entity from stroke and the prognosis for transient ischaemic attack patients have been challenged. In addition, clinical trials have clarified that modern transient ischaemic attack management is more complex than in the past, with the addition of newer pharmacological options to the stroke prevention armamentarium. Recent information regarding newer antiplatelet agents is reviewed in this article, along with results of clinical trials pertaining to warfarin in stroke prevention. The evolving role of statins, ACE inhibitors and estrogen replacement is reviewed. Finally, the appropriate use of surgery following transient ischaemic attacks is outlined. Recent studies have shown that many patients will benefit from a multimodal pharmacological approach following transient cerebral ischaemia, and the potential for combination therapy is highlighted.

UR - http://www.scopus.com/inward/record.url?scp=0037266111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037266111&partnerID=8YFLogxK

U2 - 10.2165/00023210-200317050-00001

DO - 10.2165/00023210-200317050-00001

M3 - Article

C2 - 12665389

AN - SCOPUS:0037266111

VL - 17

SP - 293

EP - 305

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -